Eric P. Winer MD

Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital

35 Park StreetNew Haven, CT 06510
Phone+1 617-632-6876
Fax+1 617-632-1930

Dr. Winer is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Winer's full profile Already have an account?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1987 - 1989
Yale-New Haven Medical CenterResidency, Internal Medicine, 1984 - 1987
Yale-New Haven Medical CenterInternship, Internal Medicine, 1983 - 1984
Yale School of MedicineClass of 1983

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

ME State Medical License Current
CT State Medical License 2021 - 2026
MA State Medical License 1997 - 2023
NC State Medical License 1987 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
COMPLETED
PHASE2
Educational Interventions for Patients With DCIS
COMPLETED
NA
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
COMPLETED
PHASE2

Publications & Presentations

PubMed

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/...
Nadine Tung, Fengmin Zhao, Angela DeMichele, Aleix Prat, Eric P Winer
Journal of Clinical Oncology. 2026-08-20
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Paolo Tarantino, Tianyu Li, Esther Ritah Ogayo, Tasnim Rahman, Molly K DiLullo
JAMA Oncology. 2026-08-01
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer.
Megan E Tesch, Noah Graham, Craig Snow, Catherine E Stever, Tonia S Parker
Breast Cancer Research and Treatment. 2026-07-30

Journal Articles

Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer
Eric P Winer, Louise C Walter, Mina S Sedrak, Tanya M Wildes, Stuart M Lichtman, Kathryn J Ruddy, JAMA Oncology
Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Sara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, JAMA Oncology
Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study
M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology

Lectures

Breast Cancer, New Horizons, Current Controversies
Harvard Medical School, Boston, Massachusetts - 7/11/2013
35th Annual CTRC-AACR San Antonio Breast Cancer Symposium(SABCS)
UT Health Science Center San Antonio, San Antonio, Texas - 12/4/2012
Breast Cancer, New Horizons, Current Controversies
Harvard Medical School, Boston, Massachusetts - 7/12/2012

Press Mentions

Women’s Health Research at Yale Funds Projects on Obesity and Ovarian Aging, Diabetes, Cancers, and AutoimmunityJuly 17th, 2026
Smilow Cancer Hospital at Greenwich Hospital Celebrates Beginning of Construction with Transformation Kickoff CeremonyApril 9th, 2026
Community Collaboration Supports Prostate Cancer Rally in New HavenJanuary 5th, 2026